A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...

EXPERTS have warned over hundreds rushed to hospital after using weight loss jabs – as half a million Brits now use the ...

Some people may turn to private healthcare providers in order to get their hands on the weight loss jabs. However, Britons ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Harvard experts highlight the broad health benefits of exercise beyond weight loss, even with new diet drugs available.

In recent research, semaglutide showed a higher effectiveness for weight loss than older injections, with the potential for a 15% weight loss after 68 weeks in adults with a BMI of 30 or greater [1].

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

A woman who waited for four years on an NHS waiting list for weight-loss support has said she believes she could have avoided developing type 2 diabetes if she was given help sooner. Hannah Baker, 44, ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...